Document is current
Any future updates will be listed below
-
Authors
Dinah, Christiana https://orcid.org/0000-0002-0815-4771
Dodds, Melanie https://orcid.org/0009-0007-8748-5299
Lotery, Andrew https://orcid.org/0000-0001-5541-4305
Salvatore, Serena
Fletcher, Emily
Lake, Alice V. R. https://orcid.org/0000-0002-6341-8661
Parker, Antony
Paris Pereira, Liliana
Retiere, Anne-Cecile
Saffar, Insaf
Arrisi, Pablo
,
Dias, Indra
Antcliff, Richard
Ghanchi, Faruque
Talks, James
Brand, Chris
Lobo, Aires
Downey, Louise
Jones, Colin
George, Sheena
Patwardhan, Ashish
Osoba, Yinka
Ramasamy, Balasubramanian
Chi, Gloria C.
-
Funding
Funding for this research was provided by:
Roche
- License Information
-
More Information
Article History
Received: 13 September 2024
Revised: 12 September 2025
Accepted: 15 October 2025
First Online: 14 November 2025
Competing interests
: CD: Consultant for AbbVie, Astellas, Boehringher Ingelheim, Johnson & Johnson, Ocular Therapeutix, and Roche; Research grants from Apellis, Roche, and Topcon; speaker fees and honoraria from Apellis, Bayer, Heidelberg, Roche, and Topcon; MD: Employee of Medisoft; AL: Consultant for Apellis, Eyebio, Johnson & Johnson, Outlook Therapeutics, and Roche; SS: Speaker fees and honoraria from Alimera Sciences, Bayer, and Roche; EF: Travel and speaker funds from Roche; AVRL: Employee of Medisoft; AP: Employee of Roche; LPP: Employee and shareholder of Genentech Inc.; ACR: Employee of Roche; IS: Employee of Roche; PA, GC: Employees of Genentech Inc.
